Novo Nordisk A/S
NOVO-B
Kedudukan dalam Saham
#108
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Harga Saham
$39.53
Modal Pasaran
$174.45B
Perubahan (1 hari)
0.75%
Perubahan (1 tahun)
-25.98%
Negara
DK
Perdagangan Novo Nordisk A/S (NOVO-B)
Kategori
Healthcare
Nisbah P/E bagi Novo Nordisk A/S (NOVO-B)
Nisbah P/E pada February 2026 TTM: 13.47
Menurut laporan kewangan dan harga saham terkini Novo Nordisk A/S, nisbah P/E semasa (TTM) ialah 13.47. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 27.53.
Sejarah nisbah P/E bagi Novo Nordisk A/S dari 2001 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 13.47 | -4.44% |
| 2025 | 14.10 | -48.77% |
| 2024 | 27.53 | -26.39% |
| 2023 | 37.40 | -2.28% |
| 2022 | 38.27 | 8.25% |
| 2021 | 35.35 | 49.61% |
| 2020 | 23.63 | 0.26% |
| 2019 | 23.57 | 23.65% |
| 2018 | 19.06 | -12.01% |
| 2017 | 21.66 | 27.49% |
| 2016 | 16.99 | -42.39% |
| 2015 | 29.49 | 14.43% |
| 2014 | 25.77 | 21.85% |
| 2013 | 21.15 | -11.44% |
| 2012 | 23.88 | 9.42% |
| 2011 | 21.83 | -13.90% |
| 2010 | 25.35 | 37.23% |
| 2009 | 18.48 | 6.65% |
| 2008 | 17.32 | -27.90% |
| 2007 | 24.03 | 1.28% |
| 2006 | 23.72 | 19.31% |
| 2005 | 19.88 | -0.71% |
| 2004 | 20.02 | 18.71% |
| 2003 | 16.87 | -2.64% |
| 2002 | 17.33 | -43.27% |
| 2001 | 30.54 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 40.53 | 200.79% |
US
|
|
| 38.50 | 185.71% |
US
|
|
| 79.88 | 492.83% |
US
|
|
| 116.96 | 768.02% |
US
|
|
| 22.25 | 65.12% |
CH
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.